Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer’s Disease and AD-Related Dementias (PAR 23-274)

NIA is thrilled to announce the new Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer’s Disease and AD-Related Dementias (PAR 23-274) funding opportunity. This funding opportunity supports the bundling of Phase 1 through Phase 2a clinical trials to help streamline and accelerate the evaluation of promising novel Alzheimer’s and related dementias drug candidates. The first application due date is Feb. 21, 2024.

This funding opportunity award mechanism requires that studies meet preapproved safety and tolerability milestones to advance from Phase 1 (UG3) to the next phase (UH3). This approach aims for a more “seamless” transition by combining these independent studies into a single award and avoiding a lapse in funding or unnecessary time delays after successful Phase 1 studies are completed.

Researchers interested in applying for this funding opportunity should email Akanni or Laurie to discuss their ideas and program requirements at least eight weeks prior to the submission deadline of Feb. 21.